 Connection
Peter Crooks to Allosteric Regulation
This is a "connection" page, showing publications Peter Crooks has written about Allosteric Regulation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.077 |
|
|
|
-
Peng C, Kimbrell MR, Tian C, Pack TF, Crooks PA, Fifer EK, Papke RL. Multiple modes of a7 nAChR noncompetitive antagonism of control agonist-evoked and allosterically enhanced currents. Mol Pharmacol. 2013 Sep; 84(3):459-75.
Score: 0.029
-
Wooters TE, Smith AM, Pivavarchyk M, Siripurapu KB, McIntosh JM, Zhang Z, Crooks PA, Bardo MT, Dwoskin LP. bPiDI: a novel selective a6?2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse. Br J Pharmacol. 2011 May; 163(2):346-57.
Score: 0.025
-
Smith AM, Dhawan GK, Zhang Z, Siripurapu KB, Crooks PA, Dwoskin LP. The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices. Biochem Pharmacol. 2009 Oct 01; 78(7):889-97.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|